RepAs of September 30, 2025, MoonLake held cash, cash equivalents and short-term marketable debt securities of $380.5 million. The Company expects its cash, cash equivalents and short-term marketable securities, together with committed capital under a previously announced debt facility with Hercules Capital, to be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2027
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics upgraded to Buy from Neutral at H.C. Wainwright
- Buy/Sell: Wall Street’s top 10 stock calls this week
- MoonLake Immunotherapeutics downgraded to Sell from Neutral at Citi
- Moonlake Immunotherapeutics Advances Psoriatic Arthritis Treatment with Sonelokimab Study
- MoonLake Immunotherapeutics Advances with Promising Sonelokimab Study in Adolescents